Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07228832 · ClinicalTrials.gov registry record · Phase 3
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
A Phase 3 study of Metastatic Colorectal Cancer (CRC), sponsored by Summit Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT07228832: Recruiting Phase 3 study of Metastatic Colorectal Cancer (CRC), sponsored by Summit Therapeutics.
NCT07228832 is a Phase 3 study of Metastatic Colorectal Cancer (CRC) that is actively recruiting participants, run by Summit Therapeutics. The registered enrollment target is 600 participants, above the 107-participant average among 5 other Metastatic Colorectal Cancer (CRC) trials with a reported enrollment target (461% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07228832, a Phase 3 study of Metastatic Colorectal Cancer (CRC), is actively recruiting participants, sponsored by Summit Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer(HARMONi-GI3)
Primary Outcome
Progression-free survival (PFS) assessed by IRRC per RECIST v1.1
Conditions Studied
Interventions
- DRUG Drug: Ivonescimab Injection
- DRUG Drug: Bevacizumab Injection
Study Locations (20)
California
- Clinical Study Site - Beverly Hills
- Clinical Study Site - Cerritos
- Clinical Study Site - Corona
- Clinical Study Site - Duarte
- Clinical Study Site - Huntington Beach
- Clinical Study Site - Irvine
- Clinical Study Site - Irvine
- Clinical Study Site - Los Angeles
- Clinical Study Site - Murrieta
- Clinical Study Site - Orange
- Clinical Study Site - Pasadena
- Clinical Study Site - Torrance
- Clinical Study Site - Upland
- Clinical Study Site - West Hollywood
Connecticut
- Clinical Study Site - New Haven
- Clinical Study Site - Norwich
Florida
- Clinical Study Site - Hialeah
- Clinical Study Site - Port Saint Lucie
Arizona
- Clinical Study Site - Goodyear
Georgia
- Clinical Study Site - Newnan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2025-11-18 |
| Est. Completion | 2029-11-30 |
| Phase | Phase 3 |
What NCT07228832 shows while recruiting
NCT07228832 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 107-participant average among 5 other Metastatic Colorectal Cancer (CRC) trials with a reported enrollment target (461% higher).
The record links to 1 condition, with Metastatic Colorectal Cancer (CRC) appearing as the primary indexed condition, and to 2 interventions - of which Drug: Ivonescimab Injection is the first listed.
NCT07228832 names 20 study sites across 5 states, led by California, Connecticut, Florida.
Frequently Asked Questions
What is clinical trial NCT07228832 about?
NCT07228832 is a clinical study titled "Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer". A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer(HARMONi-GI3)
What is the current status of trial NCT07228832?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2025-11-18. Estimated completion is 2029-11-30.
What conditions does trial NCT07228832 study?
This clinical trial studies the following conditions: Metastatic Colorectal Cancer (CRC).
What interventions are being tested in trial NCT07228832?
The interventions under investigation include: Drug: Ivonescimab Injection (DRUG), Drug: Bevacizumab Injection (DRUG).
Who is sponsoring clinical trial NCT07228832?
This trial is sponsored by Summit Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07228832 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Cancer (CRC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy
RECRUITING · Early Phase 1
-
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
RECRUITING · Phase 1
-
5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
RECRUITING · Phase 2
-
Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer
RECRUITING · Phase 2
-
Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI